NCT03197636View on ClinicalTrials.gov

Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

August 11, 2017

Primary Completion Date

November 1, 2021

Study Completion Date

February 1, 2022

Conditions
Malignant Melanoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.

Trial Locations (1)

8000

AUH, Aarhus

All Listed Sponsors
lead

Aarhus University Hospital

OTHER

NCT03197636 - Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients | Biotech Hunter | Biotech Hunter